Harm Wienbergen

Learn More
Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use. It has been approved for the prevention of venous thromboembolism in patients undergoing orthopedic surgery and for the initial therapy of venous thromboembolism. In randomized clinical trials the value of fondaparinux in the(More)
Networked activity trackers have become an important tool for assessing physical activity, as part of behavior change interventions, within epidemiological studies, or driven by personal interest. However the use of activity trackers is often abandoned after a few months, and their effect on health behavior is unclear. We conducted a longitudinal study(More)
  • 1